The RAPID‑VAC project, with a four‑year execution period, is funded under the 2025 Missions Science and Innovation call (resolution from December 2025) and was created to address this challenge.
This project is led by Certest and developed in consortium with other biotechnology companies such as Virnóstica, Nostrum Biodiscovery, Curapath, and Syngoi Technologies, as well as with the participation of top‑tier scientific and technological institutions within the Spanish R&D&I system.
The goal of RAPID‑VAC is to develop a sovereign, agile, and robust autonomous platform with a direct impact on health security, enabling the development and production of RNA vaccines against emerging pathogens or biological threats, reducing response times and avoiding external dependency.
